Ann: Letter to Shareholders, page-38

I would say they have lead investors down the garden path knowing full well the most recent trials will deduce nothing more than what we already knew (without a forthcoming deal). Hence why no directors ever bought significant shares in recent times other than obligatory credit raising to keep their jobs.

The trials have been setup to replicate and yet again pass safety with a few other “interesting” immune changes. Now the explanation is sorry there are no available assays to tell us what BIT225 is really capable of in regards to flushing out reservoirs (the main game). Oopsies but thanks for paying our salaries as we dragged this out as long as we possibly could while giving investors the finger with coming weeks and imminent communication.

Yes you are correct, Biotron has no commercially minded CEO who can speak, strategise & deliver to a commercially focused audience on ASX.. now for over 20 years, the bank balance approaching zero and SP 3cents (having originally listed at 50 cents when MM started) .